Rosacea Treatments - Non-Approved Therapies
Treatment - Non-approved therapies
The following treatments have been described in literature as successful in
rosacea patients, but they have not been approved for this disease, and large
controlled surveys are lacking. These suggestions should not in any way
encourage or promote the off-label use of these products.
Topical
Tacrolimus, an immunomodulator which, as a topical agent, is approved for
the treatment of atopic eczema, has been shown to be effective in patients
with steroid-induced rosacea. Tacrolimus ointment has been applied in a
concentration of 0,075% and 0,1% for rosacea.
Ascomycin, another immunomodulator, has been reported to be effective
in rosacea in a concentration of 1%.Infestation with demodex folliculorum
mites has been discussed as an etiologic factor in some cases of rosacea or
rosacea-like skin lesions.
Thus, antiinfectives such as permethrin 5% cream, lindane and benzoyl
benzoat have been recommended for stage II-rosacea.
Systemic
Dapsone, an antibiotic and antiparasitic agent, has been reported effective
in a dosage of 100 mg daily in rosacea fulminans.
Clonidine, a centrally active antihypertensive agent, has been shown to
reduce facial flushing. However small doses, which do not cause a decrease
in blood pressure, are said to have little or no effect.
Propranolol, a non-cardioselective beta-blocker has also been reported to
be helpful in reducing flushing. A dosage of 40 mg twice daily has been
recommended for this indication.
Orally administered metronidazole has been reported effective in a dosage
of 500 mg daily for stages II and III. A treatment duration of up to 20 – 60
days was required. This drug is not approved for a treatment duration
longer than 6 days, and it displays considerable side effects.
More can be found at:
http://rosacea.dermis.net/content/e04treatment/
e10non_approved/index_eng.html
The following treatments have been described in literature as successful in
rosacea patients, but they have not been approved for this disease, and large
controlled surveys are lacking. These suggestions should not in any way
encourage or promote the off-label use of these products.
Topical
Tacrolimus, an immunomodulator which, as a topical agent, is approved for
the treatment of atopic eczema, has been shown to be effective in patients
with steroid-induced rosacea. Tacrolimus ointment has been applied in a
concentration of 0,075% and 0,1% for rosacea.
Ascomycin, another immunomodulator, has been reported to be effective
in rosacea in a concentration of 1%.Infestation with demodex folliculorum
mites has been discussed as an etiologic factor in some cases of rosacea or
rosacea-like skin lesions.
Thus, antiinfectives such as permethrin 5% cream, lindane and benzoyl
benzoat have been recommended for stage II-rosacea.
Systemic
Dapsone, an antibiotic and antiparasitic agent, has been reported effective
in a dosage of 100 mg daily in rosacea fulminans.
Clonidine, a centrally active antihypertensive agent, has been shown to
reduce facial flushing. However small doses, which do not cause a decrease
in blood pressure, are said to have little or no effect.
Propranolol, a non-cardioselective beta-blocker has also been reported to
be helpful in reducing flushing. A dosage of 40 mg twice daily has been
recommended for this indication.
Orally administered metronidazole has been reported effective in a dosage
of 500 mg daily for stages II and III. A treatment duration of up to 20 – 60
days was required. This drug is not approved for a treatment duration
longer than 6 days, and it displays considerable side effects.
More can be found at:
http://rosacea.dermis.net/content/e04treatment/
e10non_approved/index_eng.html
posted by Madison at 11:02 AM
<< Home